Claims
- 1. A pharmaceutical composition which comprises an effective phospholipase A.sub.2 inhibiting amount of a benzenesulfonamide derivative represented by the general formula: ##STR192## wherein R.sup.1 stands for a hydrogen atom, a cyano, nitro hydroxy group, a halogen atom, a lower alkoxy group, an acyloxy group wherein said acyl moiety is a residue of an organic saturated or unsaturated aliphatic, carbocyclic or heteroaryl carboxylic acid wherein the hetero atom is oxygen, nitrogen or sulfur, --SO.sub.2 --R.sup.8 wherein R.sup.8 stands for a lower alkyl group, a heteroaryl wherein the hetero atom is a nitrogen, oxygen or sulfur atom, a glycyloxy group, or a group represented by the formula: ##STR193## wherein p is an integer of 1 to 3; n is an integer of 1 to 4;
- R.sup.2 stands for a hydrogen atom or a pyridyl group.;
- R.sup.3 stands for a hydrogen atom or a lower alkyl, cyano or pyridyl group;
- R.sup.4 stands for a hydrogen atom or a lower alkyl group;
- R.sup.5 and R.sup.6 may be the same or different from each other and each stand for a hydrogen atom, a lower alkyl group, a group represented by the formula: --(CH.sub.2).sub.q --A wherein q is an integer of 1 to 4,
- and A stands for a hydroxyl group, a group represented by the formula: ##STR194## wherein R.sup.9 and R.sup.10 may be the same or different and each stand for a hydrogen atom or a lower alkyl group; or
- R.sup.5 and R.sup.6 each stand for an unsubstituted cycloalkyl group, or a cycloalkyl substituted with a lower alkyl or halogen or condensed with an aromatic ring, a bicycloalkyl, or tricycloalkyl, said bicycloalkyl or tricycloalkyl being an aliphatic saturated hydrocarbon group made of two or three rings, respectively, with at least two carbon atoms being common to each ring;
- a plurality of R.sup.7 groups each independently stand for a hydrogen atom, a lower alkyl group, a lower alkoxy group or a halogen atom; and r is an integer of 1 to 2, provided that when r is 2, the two R.sup.7 groups may form a cyclohexenyl or phenyl ring together with two adjacent carbon atoms constituting the benzene ring; and
- m is an integer of 1 to 2; or a pharmacologically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- 2. The composition as set forth in claim 1, wherein R.sup.1 is a group represented by the formula: --SO.sub.2 --R.sup.8 (wherein R.sup.8 stands for a lower alkyl group), an imidazolyl, cyano or nitro group, a halogen or hydrogen atom or a hydroxyl group.
- 3. A benzenesulfonamide derivative or a pharmacologically acceptable salt thereof as set forth in claim 1, wherein R.sup.1 is a group represented by the formula: --SO.sub.2 CH.sub.3.
- 4. The composition as set forth in claim 1, wherein R.sup.1 is a --SO.sub.2 CH.sub.3 group, n is 1 and the --SO.sub.2 CH.sub.3 group is present at the p-position.
- 5. The composition as set forth in any of claims 1, 2, 3 or 4, wherein R.sup.2 and R.sup.3 are each a hydrogen atom and m is 1.
- 6. The composition as set forth in any of claims 1, 2, 3 or 4, wherein R.sup.4 is a methyl group.
- 7. The composition as set forth in any of claims 1, 2, 3 or 4, wherein R.sup.4 is an isopropyl.
- 8. The composition as set forth in any of claims 1, 2, 3 or 4, wherein R.sup.7 is a hydrogen atom.
- 9. The composition as set forth in any of claims 1, 2, 3 or 4, wherein R.sup.5 is a hydrogen atom or a methyl group and R.sup.6 is a substituted or unsubstituted arylalkyl group or an unsubstituted or substituted cycloalkyl group.
- 10. The composition as set forth in claim 1, wherein the derivative is
- N-cycloheptyl-4-{N-methly-N-[(E)-3-(4-methylsulfonylphenyl)-2-propenoyl]amino}benzenesulfonamide,
- N-[2-(2-pyridyl)ethyl]-4-{N-methyl-N-[(E)-3-(4-methylsulfonylphenyl)-2-propenoyl]amion)benzenesulfonamide,
- (E)-N-methyl-N-[4-(4-benzyl-1homopiperazinyl)-sulfonyphenyl]-3-(4-methylsulfony;phenyl)-2-propenamide, and
- (E)-N-mehtyl-N-{4-[4(2-phenylethyl)piperazinyl]-sulfonylphenyl}-3-(4-methylsulfonylphenyl)-2-propenamide.
- 11. The composition as set forth in any of claims 1, 2, 3 or 4, wherein R.sup.5 is a hydrogen atom or a methyl group.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2-27071 |
Feb 1991 |
JPX |
|
Parent Case Info
This application is a divisional of application Ser. No. 08/161,817, filed on Dec. 6, 1993, now U.S. Pat. No. 5,530,781 which was a divisional of application Ser. No. 07/768,515, filed Sep. 26, 1991, now U.S. Pat. No. 5,281,426, the entire contents of which are hereby incorporated by reference.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4925861 |
Hiyashi et al. |
May 1990 |
|
4992469 |
Ozawa et al. |
Feb 1991 |
|
5281626 |
Oinuma et al. |
Jan 1994 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
227431 |
Jul 1987 |
EPX |
248597 |
Dec 1987 |
EPX |
255749 |
Dec 1985 |
JPX |
2175466 |
Aug 1987 |
JPX |
632968 |
Jan 1988 |
JPX |
325584 |
Oct 1988 |
JPX |
Non-Patent Literature Citations (3)
Entry |
Chemical Abstract of article by Azerbaev et al. titled, "Sulfanilamide derivatives based on acteylenic amines", Tr. Inst. Khim. Akad. Kaz. SSR, vol. 19, pp. 60-63 1967. |
R.J. Cremlyn et al., J. Chem. Soc. Pak., vol. 7, No. 2, 1985, pp. 111-124. |
Naoya Yoda et al., J. Polymer Science, Part A, vol. 3, pp. 2229-2242 (1965). |
Divisions (2)
|
Number |
Date |
Country |
Parent |
161817 |
Dec 1993 |
|
Parent |
768515 |
Sep 1991 |
|